Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash from Operations: 2013-2025

Historic Cash from Operations for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to -$152.9 million.

  • KalVista Pharmaceuticals' Cash from Operations fell 167.22% to -$40.4 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$135.3 million, marking a year-over-year decrease of 51.66%. This contributed to the annual value of -$152.9 million for FY2025, which is 71.36% down from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported Cash from Operations of -$152.9 million as of FY2025, which was down 71.36% from -$89.2 million recorded in FY2024.
  • Over the past 5 years, KalVista Pharmaceuticals' Cash from Operations peaked at -$30.2 million during FY2021, and registered a low of -$152.9 million during FY2025.
  • Its 3-year average for Cash from Operations is -$105.8 million, with a median of -$89.2 million in 2024.
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Cash from Operations skyrocketed by 32.68% in 2021, and later slumped by 158.97% in 2022.
  • Yearly analysis of 5 years shows KalVista Pharmaceuticals' Cash from Operations stood at -$30.2 million in 2021, then slumped by 158.97% to -$78.1 million in 2022, then grew by 3.68% to -$75.3 million in 2023, then decreased by 18.56% to -$89.2 million in 2024, then crashed by 71.36% to -$152.9 million in 2025.